Top Stock Reports for Exxon Mobil, Texas Instruments & GlaxoSmithKline
Tuesday, June 22, 2021
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil (XOM), Texas Instruments (TXN) and GlaxoSmithKline (GSK). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Exxon Mobil have outperformed the Zacks Integrated International Oil industry in the year-to-date period (+59.9% vs. +33.3%). The Zacks analyst believes that major discoveries in the Stabroek Block have enhanced prospects for Exxon Mobil's upstream businesses.
The firm recently announced another significant oil discovery at the Longtail-3 well, offshore Guyana. The new find added to the prior estimate of gross recoverable resource of 9 billion barrels of oil equivalent in the Stabroek block. The firm also has a strong presence in the prolific Permian, where it continues to lower its fracking & drilling costs.
Texas Instruments’ shares have gained +17.4% over the last six months against the Zacks General Semiconductor industry’s gain of +30%. The Zacks analyst believes that Texas Instruments is benefiting from growth in the personal electronics market on the back of the pandemic-led work-from-home trend.
Further, solid momentum across the Analog segment due to robust signal chain and power product lines, has been boosting the top line. The company’s portfolio of long-lived products and efficient manufacturing strategies are other major positives. However, coronavirus related uncertainties remain major headwinds.
Shares of GlaxoSmithKline have gained +10.8% in the past three months against the Zacks Large Cap Pharmaceuticals industry’s gain of +11.2%. The Zacks analyst believes that Glaxo’s new and specialty products like Nucala, Trelegy Ellipta, Shingrix and Juluca have been driving sales, making up for a decline in Established Pharmaceuticals due to generic erosion.
Glaxo has several new drug/line extension approvals in the pipeline in 2021, which is expected to boost the top line in the long term. However, generic competition to Advair has been weighing on the sales of Glaxo’s respiratory products. Further, the company’s HIV drugs have been facing increased competition in the market.
Other noteworthy reports we are featuring today include Norfolk Southern (NSC), Edwards Lifesciences (EW) and Corning (GLW).
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
The Zacks analyst is impressed with the company's strong free cash flow generating abilities. However, weakness of the coal segment is concerning.
The Zacks analyst is optimistic about Edwards' TAVR segment performing well despite the pandemic-led business challenges.
Per the Zacks analyst, Corning is likely to continue benefiting from strong demand and positive momentum across its businesses through 2021 despite headwinds in the Optical Communications segment.
Per the Zacks analyst, FEMSA is taking prudent steps to diversify its product portfolio through growth via acquisition strategy.
Per the Zacks analyst, business servicing wins, synergies from strategic buyouts and global footprint will continue to aid State Street amid lower interest rates and tough operating backdrop.
Per the Zacks analyst, its strategic buyouts have helped it enhance its digital capabilities and diversify its business.
Per the Zacks analyst, company's systematic capital investment plan for infrastructure development bolsters growth prospects.
The Zacks analyst believes that Hess' major oil discoveries at the Stabroek Block offshore Guyana, will generate astronomical cash flows. Also, its profitable midstream assets are a major positive.
Jabil is benefiting from end-market strength and solid operational execution. The Zacks analyst believes strong growth prospects in mobility and cloud-connected devices are major drivers.
Diverse geographical mix and solid backlog along with restructuring efforts like sale of fabrics business aimed to streamline portfolio are likely to aid Adient's profits, per the Zacks analyst.
Per the Zacks analyst, Jazz's highest revenue generator, Xyrem, is set to face generic competition starting 2023 following the expiry of patents in the United States.
Per the Zacks analyst, Aspen is suffering from COVID-19 crisis-led supply chain disruptions. Moreover, weakness in chemical and refining industry is a headwind.
Per the Zacks analyst, Century Aluminum faces headwind from higher alumina costs, which will increase its operating expenses and weigh on margins. The high price of power is another concern.
Click to get this free report
Exxon Mobil Corporation (XOM): Free Stock Analysis Report
Texas Instruments Incorporated (TXN): Free Stock Analysis Report
Norfolk Southern Corporation (NSC): Free Stock Analysis Report
GlaxoSmithKline plc (GSK): Free Stock Analysis Report
Corning Incorporated (GLW): Free Stock Analysis Report
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.